The True Cost of GLP-1 Medications in 2026 (Ozempic, Wegovy, Mounjaro, Zepbound)

What GLP-1 weight-loss and diabetes drugs actually cost in 2026 — list price, with insurance, with manufacturer coupons, and the real out-of-pocket totals US patients are paying.

By Symptom Advisory Editorial Team — last reviewed August 18, 2026 — 13 min read

The True Cost of GLP-1 Medications in 2026 (Ozempic, Wegovy, Mounjaro, Zepbound)

Key Takeaways

  • Cash list prices in 2026: Wegovy $1,349/mo, Zepbound $1,086/mo, Ozempic $968/mo, Mounjaro $1,069/mo.
  • Eli Lilly's LillyDirect Self-Pay vials cut Zepbound to $349–$499/month for the lower doses.
  • Novo Nordisk's NovoCare Pharmacy now offers Wegovy at $499/month for cash-pay patients without insurance.
  • Medicare Part D covers Ozempic and Mounjaro for type 2 diabetes — but still does NOT cover Wegovy or Zepbound for weight loss alone.
  • Medicare DOES cover Wegovy when prescribed for cardiovascular risk reduction in patients with established CVD (since March 2024).
  • Compounded semaglutide is no longer legally available after FDA's October 2024 enforcement decision, with limited exceptions ending in 2025.
  • Most commercial insurers require BMI ≥30 (or ≥27 with comorbidity) AND prior authorization for weight-loss coverage.
  • The average insured patient with coverage pays $25–$75/month after manufacturer savings cards.

GLP-1 receptor agonists are the most-prescribed new drug class in a generation. In 2026, more than 12% of US adults have used one. They are also extraordinarily expensive: list prices for Wegovy and Zepbound exceed $1,000 per month, and the patchwork of insurance coverage, manufacturer programs, and now-illegal compounded versions makes the real cost difficult to pin down. This guide breaks down what these drugs actually cost in 2026 — and how to pay the least legally.

The big four GLP-1s

Brand Manufacturer Active ingredient FDA indications
Ozempic Novo Nordisk Semaglutide Type 2 diabetes; CVD risk reduction in T2D
Wegovy Novo Nordisk Semaglutide Chronic weight management; CVD risk reduction in adults with overweight/obesity + CVD
Mounjaro Eli Lilly Tirzepatide Type 2 diabetes
Zepbound Eli Lilly Tirzepatide Chronic weight management; obstructive sleep apnea in obesity

Ozempic and Wegovy are the same molecule (semaglutide), differently dosed and labeled. Same for Mounjaro and Zepbound (tirzepatide). The FDA labels matter for insurance coverage.

2026 cash list prices (no insurance)

  • Wegovy: $1,349.02/month (any dose)
  • Ozempic: $968.52/month
  • Zepbound (pen): $1,086.37/month
  • Zepbound (LillyDirect Self-Pay vials): $349 (2.5 mg) / $499 (5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)
  • Mounjaro: $1,069.08/month
  • Wegovy via NovoCare Pharmacy (cash): $499/month all doses

The Self-Pay vial program from LillyDirect (launched late 2024, expanded through 2025) is the single biggest cost reduction in the category. You order through LillyDirect.com, draw from a vial with a syringe, and skip the autoinjector pen.

With commercial insurance

If your plan covers GLP-1s for your indication, manufacturer savings cards bring most patients to $25/month for the first 12 months:

  • Wegovy NovoCare Savings Card: as low as $0 for first month, $25/month after, capped at $225 savings/month, 12 months max.
  • Zepbound Savings Card: as low as $25/month for covered patients (max $150 off/month).
  • Ozempic Savings Card: $25/month for the first 24 months (commercial insurance only, T2D required).
  • Mounjaro Savings Card: $25/month for up to 13 fills (commercial insurance only).

Government insurance (Medicare, Medicaid, TRICARE) is excluded from manufacturer savings cards by federal anti-kickback law.

Without insurance coverage

Three legitimate paths:

  1. LillyDirect Self-Pay (Zepbound): $349–$499/month for vials. Best value if you want tirzepatide.
  2. NovoCare Pharmacy (Wegovy cash): $499/month for all doses. Best value if you specifically need semaglutide.
  3. Patient assistance programs: Both Novo Nordisk and Eli Lilly have income-based PAPs that can provide free medication to uninsured patients earning <400% of the federal poverty level. Applications take 2–4 weeks.

What about compounded semaglutide and tirzepatide?

The FDA removed semaglutide and tirzepatide from the official drug shortage list in October 2024, ending the legal basis for most compounded versions. After enforcement deadlines in 2025, compounded GLP-1s from large 503B outsourcing facilities are no longer legally available, and 503A compounding pharmacies cannot make "essentially copies" of FDA-approved drugs.

Some compounders continue to offer "semaglutide blends" with vitamin B12 or other additives, claiming they qualify as personalized medicine. The FDA, FTC, and most state pharmacy boards have stated this practice is not lawful. Quality and dosing accuracy in tested compounded products has been variable — a 2024 JAMA analysis found dosing errors in 22% of samples.

Bottom line: if you're paying $200/month for compounded "semaglutide" online in 2026, you're likely getting an unregulated product, and the legal landscape has shifted against the supplier.

Medicare coverage in 2026

  • Type 2 diabetes: Medicare Part D covers Ozempic and Mounjaro (formulary tiering varies by plan). Average copay $40–$120/month.
  • Weight loss alone: Still not covered in 2026. The Medicare Modernization Act explicitly excludes weight-loss drugs.
  • Cardiovascular risk reduction: Since CMS's March 2024 memo, Medicare Part D covers Wegovy for adults with established cardiovascular disease and overweight/obesity (BMI ≥27). This requires diagnosis documentation but does not require diabetes.
  • Sleep apnea: Zepbound was approved for OSA in obesity in late 2024. Some Medicare Part D plans began covering it for this indication in 2025; coverage is uneven going into 2026.

Medicaid coverage

State-by-state. As of January 2026, 24 states cover at least one GLP-1 for obesity (up from 16 in 2024). Most require BMI ≥35, prior authorization, and documented attempts at lifestyle intervention.

Commercial insurance: what to expect

  • Coverage rate (2026): ~52% of large employer plans cover GLP-1s for weight loss, up from 42% in 2024. Coverage for diabetes is near-universal.
  • Prior authorization: Required by 89% of plans. Typical criteria: BMI ≥30 (or ≥27 with comorbidity), failed lifestyle program, and ongoing reauthorization every 6 months requiring 5% weight loss.
  • Step therapy: Some plans require trying older/cheaper agents (phentermine, dulaglutide, oral semaglutide) first.

The hidden costs

  • Lab work: baseline and every 3–6 months — usually $0 with insurance, $150–$300 cash.
  • Telehealth follow-ups: $30–$80/visit if not insurance-covered.
  • Replacement food / Whey protein: the appetite-suppressing effect makes nutrition a real concern; many users add a protein supplement and a multivitamin (~$30/month).
  • Discontinuation rebound: stopping leads to ~⅔ weight regain within 12 months in clinical trials. Plan for long-term use or a maintenance strategy.

How to minimize what you pay

  1. Match your indication — if you have T2D, get Ozempic/Mounjaro (better-covered) rather than Wegovy/Zepbound.
  2. Use the manufacturer cards — never pay list price if you have commercial insurance.
  3. For uninsured tirzepatide users: LillyDirect vials at $349/$499 beat every other legal option.
  4. For uninsured semaglutide users: NovoCare at $499 is the legitimate cheapest path.
  5. Apply to the patient assistance programs if your income is <400% of FPL.
  6. Avoid compounded products unless your prescriber confirms they come from a properly licensed source for an exempt indication — most no longer qualify.

Bottom line

In 2026, the legitimate floor on GLP-1 costs is $25/month with commercial insurance + manufacturer card, or $349–$499/month for cash-pay patients via LillyDirect or NovoCare. List prices remain over $1,000/month and have not meaningfully declined despite political pressure. Coverage continues to expand for cardiovascular indications and sleep apnea, but pure weight-loss coverage in Medicare remains off the table.

Practical Checklist

  • Confirm your exact drug, dose, and indication (diabetes vs weight loss).
  • Check your insurance formulary (search 'GLP-1' or the brand name).
  • Apply for the manufacturer savings card (NovoCare or LillyDirect).
  • Compare LillyDirect Self-Pay vials vs. pen pricing.
  • Ask your prescriber about generic dulaglutide or older agents if cost is prohibitive.
  • Avoid unverified compounding pharmacies — most are now operating illegally.

Frequently Asked Questions

Will Medicare cover Wegovy in 2026?

Only when prescribed for cardiovascular risk reduction in patients with established CVD and overweight/obesity. Wegovy for weight loss alone is still not covered.

Is compounded semaglutide still legal in 2026?

Largely no. The FDA ended the shortage status in October 2024 and 503A pharmacies cannot make essentially-copies of FDA-approved drugs. Limited exemptions exist but most online compounded GLP-1s now operate outside legal bounds.

What is LillyDirect Self-Pay?

A direct-from-manufacturer program selling Zepbound vials (not pens) at $349–$499/month to cash-pay patients with a valid prescription.

How much is Ozempic with insurance?

If your plan covers it for type 2 diabetes, the manufacturer savings card brings most commercially insured patients to $25/month for up to 24 months.

Can I switch from Ozempic to Wegovy?

Yes, but coverage usually depends on indication. Switching from a diabetes prescription to a weight-loss prescription often triggers a new prior authorization.

Are GLP-1s covered for weight loss by employer plans?

About 52% of large employer plans cover them in 2026, usually with BMI thresholds and prior authorization.

What happens if I stop taking a GLP-1?

Clinical trials show roughly two-thirds of weight loss returns within 12 months of stopping. Plan for long-term use or a structured maintenance strategy.

Are oral GLP-1s cheaper?

Rybelsus (oral semaglutide) is similarly priced (~$1,000/month list) and covered for diabetes, not weight loss. New oral agents (orforglipron) are expected in late 2026.

Can I import GLP-1s from Canada or Mexico?

Personal importation of injectable GLP-1s is generally not legal in the US and counterfeits are common. Don't do it.

Sources & References

  1. Wegovy Pricing — Novo Nordisk link
  2. Zepbound Self-Pay Vials — Eli Lilly link
  3. LillyDirect Pharmacy Solutions — Eli Lilly link
  4. NovoCare Pharmacy — Novo Nordisk link
  5. Medicare Coverage of Wegovy for CVD — CMS Memorandum March 2024 link
  6. FDA Removes Semaglutide from Shortage List — FDA link
  7. FDA on Compounded GLP-1 Risks — FDA link
  8. Compounded Semaglutide Dosing Variability — JAMA 2024 link
  9. Wegovy SELECT Trial (CV Outcomes) — NEJM 2023 link
  10. Zepbound for OSA Approval — FDA link
  11. State Medicaid Coverage of Anti-Obesity Medications — KFF link
  12. STEP Trials of Semaglutide — NEJM link
  13. SURMOUNT Trials of Tirzepatide — NEJM link
  14. Weight Regain After Discontinuation — Diabetes Obesity & Metabolism link

Medical disclaimer

This article is health information for education only. It is not medical advice, a diagnosis or a treatment plan. In an emergency, call 911. Researched and drafted with AI-assisted tools and fact-checked by a human editor against the sources listed above. How we create our content.